{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=24",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 20596,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T12:41:16.193Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00694122",
      "title": "Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes",
        "Dawn Phenomenon"
      ],
      "interventions": [
        {
          "name": "Lantus (glargine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2005-06",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-10-21",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00694122"
    },
    {
      "nct_id": "NCT02253251",
      "title": "Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "KRAS-variant and microRNA binding site mutation testing",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "MiraKind",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15000,
      "start_date": "2014-09",
      "completion_date": "2035-09",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02253251"
    },
    {
      "nct_id": "NCT04394351",
      "title": "Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Esophagitis (EoE)"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 102,
      "start_date": "2020-09-01",
      "completion_date": "2024-05-14",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04394351"
    },
    {
      "nct_id": "NCT01662102",
      "title": "Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Zevalin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2012-12-11",
      "completion_date": "2013-03-05",
      "has_results": true,
      "last_update_posted_date": "2021-10-04",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 5,
      "location_summary": "Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        },
        {
          "city": "Niles",
          "state": "Illinois"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Charleston",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01662102"
    },
    {
      "nct_id": "NCT00241202",
      "title": "The Efficacy of the HIV/AIDS Symptom Management Manual",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "Acquired Immunodeficiency Syndrome"
      ],
      "interventions": [
        {
          "name": "Symptom Management Manual",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 775,
      "start_date": "2005-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2008-01-17",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Harlingen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241202"
    },
    {
      "nct_id": "NCT00130637",
      "title": "Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anterior Uveitis",
        "Arthritis, Juvenile Idiopathic",
        "Iritis",
        "Immunosuppression"
      ],
      "interventions": [
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Eye Institute (NEI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Years to 18 Years"
      },
      "enrollment_count": 6,
      "start_date": "2005-08",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2017-01-30",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130637"
    },
    {
      "nct_id": "NCT01407237",
      "title": "Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV-infection"
      ],
      "interventions": [
        {
          "name": "Angiotensin II Infusion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2012-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-08-05",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01407237"
    },
    {
      "nct_id": "NCT00002337",
      "title": "A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Vesnarinone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka America Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002337"
    },
    {
      "nct_id": "NCT00089037",
      "title": "Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "sirolimus",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2011-07-15",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00089037"
    },
    {
      "nct_id": "NCT06686472",
      "title": "Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "TL-925",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telios Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2024-10-03",
      "completion_date": "2024-12-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-13",
      "last_synced_at": "2026-10-18T12:41:16.193Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06686472"
    }
  ]
}